Vanda Pharmaceuticals announced that the FDA has granted its request for a rare formal evidentiary public hearing to review CDER’s proposal to refuse approval of the supplemental new drug application ...
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Bloomberg on MSN
Vanda Insights on oil markets, IEA report
Vandana Hari, Founder of Vanda Insights, discusses her outlook on the oil markets following a report saying the International ...
"The BYSANTI™ approval marks a significant step forward, offering patients and providers a reliable new treatment grounded in extensive clinical heritage," said Mihael H. Polymeropoulos, M.D., ...
Vanda Pharmaceuticals VNDA stock: surges 44% after FDA approves BYSANTI for Bipolar I and Schizophrenia, with patent protection until 2044 and a Q3 2026 launch.
Investing.com – Vanda Pharmaceuticals (NASDAQ: VNDA) just announced that it has received FDA-approval for its new drug known as BYSANTI. The drug is meant to treat Bipolar I manic episodes as well as ...
Feb 20 (Reuters) - The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' (VNDA.O), opens new tab drug for the treatment of two serious mental health conditions, the company said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results